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Abstract
Purpose: P-glycoprotein (Pgp) is an efflux transporter involved in transport of several
compounds across the blood–brain barrier (BBB). Loss of Pgp function with increasing age
may be involved in the development of age-related disorders, but this may differ between males
and females. Pgp function can be quantified in vivo using (R)-[11C]verapamil and positron
emission tomography. The purpose of this study was to assess global and regional effects of
both age and gender on BBB Pgp function.
Procedures: Thirty-five healthy men and women in three different age groups were included. Sixty
minutes dynamic (R)-[11C]verapamil scans with metabolite-corrected arterial plasma input curves
were acquired. Grey matter time–activity curves were fitted to a validated constrained two-tissue
compartment plasma input model, providing the volume of distribution (VT) of (R)-[
11C]verapamil as
outcome measure.
Results: Increased VT of (R)-[
11C]verapamil with aging was found in several large brain regions
in men. Young and elderly women showed comparable VT values. Young women had higher VT
compared with young men.
Conclusions: Decreased BBB Pgp is found with aging; however, effects of age on BBB Pgp
function differ between men and women.
Key words: Aging, Gender, Positron emission tomography, Blood–brain barrier, P-glycoprotein,
(R)-[11C]verapamil
Introduction
The blood–brain barrier (BBB) is composed of a tightlysealed monolayer of brain capillary endothelial cells
which, together with astrocytes and pericytes, separates the
brain from its external environment. The BBB plays an
important role in both protecting the brain and maintaining
homeostasis in the central nervous system (CNS) [1, 2]. A
key component of the system for regulating the CNS internal
milieu is the presence of several transporter systems, which
are located at the BBB and are able to transport substances
across the BBB [3].
One of the most important transporters at the BBB is the
multidrug resistance protein P-glycoprotein (Pgp), encoded
by MDR1/ABCB1 and belonging to the family of ATP-
binding cassette transporters. Pgp is located throughout the
human body in organs or tissues with an excretory and/or
barrier function, such as liver, kidney, testes and the BBBCorrespondence to: Daniëlle M. E. Assema; e-mail: d.vanassema@vumc.nl
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[4]. At the BBB, Pgp is highly expressed at the vessel walls
of the brain capillaries, where it functions as an efﬂux pump.
Pgp has the remarkable capacity to extrude a large range of
structurally and functionally unrelated compounds from the
brain. Together with its high expression, this is the main
reason that Pgp is considered to be of great importance for
protecting the brain from accumulation of potentially toxic
substances [5, 6].
Age is a risk factor for many neurodegenerative disor-
ders, such as Alzheimer’s disease (AD) and Parkinsons’s
disease (PD) [7, 8]. Progressive dysfunction of Pgp at the
BBB with increasing age could be a contributing factor in
the increasing risk of developing neurodegenerative disor-
ders with advancing age. For neurodegenerative disorders
such as AD, female gender is another risk factor. Several
studies have described a higher incidence of AD in women,
which might partly be explained by survival differences
favouring women, although hormonal differences could also
play a role [9–11]. Pgp expression is known to differ
between men and women; for example, hepatic Pgp
expression is 2.4-fold lower in females, although there are
large interindividual differences in Pgp levels [12]. However,
little is known about gender differences in Pgp function at the
BBB, which again may be under gender speciﬁc hormonal
inﬂuences [13].
Positron emission tomography (PET) with the radio-
labelled Pgp substrate (R)-[11C]verapamil is a validated
technique to measure BBB Pgp function in vivo [14, 15]. It
has been shown that the volume of distribution (VT) of (R)-
[11C]verapamil inversely reﬂects cerebral Pgp function [16].
Previous data suggest decreased cerebral Pgp function in
healthy aging [17–19] and AD [20], whilst conﬂicting
results have been obtained in PD [21, 22]. The purpose of
the present study was to further investigate global and
regional effects of age and gender on BBB Pgp function in a




Thirty-ﬁve healthy male and female subjects in three different age
groups (young subjects between 20 and 30 years, middle aged
subjects between 40 and 50 years and elderly subjects between 55
and 70 years of age) were recruited through advertisements in
newspapers and by means of ﬂyers. Of the 35 subjects, ten males
(ﬁve young and ﬁve elderly) had also been included in a previously
published pilot study of Toornvliet et al. assessing BBB Pgp
function [17]. Subjects underwent a standardized clinical assess-
ment, including medical history, family history, use of medication
and drugs of abuse, and physical and neurological examinations.
Subjects had to fulﬁl research criteria of having never been
mentally ill. All subjects had normal scores on screening laboratory
tests and urine screening for use of drugs of abuse was negative. All
subjects had a normal magnetic resonance imaging (MRI) scan, as
evaluated by a neuroradiologist. Mini-Mental State Examination
(MMSE) scores were within the normal range (MMSE 9 26) [23].
Medication at the time of scanning was not allowed, except for
medication known not to interfere with Pgp function [24, 25].
Written informed consent was obtained from all participants after a
complete written and verbal description of the study. The study was
approved by the Medical Ethics Review Committee of the VU
University Medical Center.
MRI
All subjects underwent structural MRI scans using a 1.0-T
Magnetom Impact scanner (Siemens Medical Solutions, Erlangen,
Germany) or a 1.5-T Sonata scanner (Siemens Medical Solutions,
Erlangen, Germany). Scan protocols on both scanners included an
identical coronal T1-weighted 3-D magnetization prepared rapid
acquisition gradient echo. Voxel size of the images was 0.98×
0.98×1.49 mm. These MRI scans were used for co-registration and
region-of-interest (ROI) deﬁnition.
PET
PET scans were acquired using an ECAT EXACT HR+ scanner
(Siemens/CTI, Knoxville, TN, USA) [26]. All subjects received an
indwelling radial artery cannula for arterial sampling and a venous
cannula for tracer injection. First, a 10-min transmission scan in 2D
acquisition mode was performed using three retractable rotating
line sources. This scan was used to correct the subsequent emission
scan for photon attenuation. Next, a 3D dynamic emission scan was
started simultaneously with the injection of 369±19 MBq (R)-[11C]
verapamil, performed using an infusion pump (Med-Rad, Beek, the
Netherlands). This emission scan consisted of 20 frames with
progressive increase in frame duration (1×15, 3×5, 3×10, 2×30,
3×60, 2×150, 2×300, 4×600 s; total acquisition time 60 min).
During the scan, arterial blood was withdrawn continuously using
an online sampling device (Veenstra Instruments, Joure, the
Netherlands) [27]. At set times, continuous sampling was inter-
rupted and manual samples were taken. Subject motion was
restricted by the use of a head immobilisation device, and position
of the head was checked visually at regular intervals during
scanning (using laser beams) and corrected immediately when
necessary. A more detailed description of scanning and sampling
procedures has been reported previously [20].
PET Data Analysis
All PET sinograms were corrected for dead time, tissue attenuation,
decay, scatter and randoms. PET scans were reconstructed using a
standard ﬁltered back projection (FBP) algorithm and a Hanning
ﬁlter with a cutoff at 0.5 times the Nyquist frequency. A zoom
factor of 2 and a matrix size of 256×256×63 were used, resulting
in a voxel size of 1.2×1.2×2.4 mm and a spatial resolution of
approximately 6.5 mm full width at half maximum at the centre of
the ﬁeld of view. Images were also reconstructed using a partial
volume corrected ordered subset expectation maximization (PVC
OSEM) reconstruction algorithm, a previously described and
validated method that results in improved image resolution, thereby
reducing partial volume effects (PVE) [28–30]. Co-registration of
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structural T1 MR images to corresponding PET images (using
summed FBP or PVC OSEM reconstructed images of frames 3–12)
and segmentation of the co-registered MRI into grey matter, white
matter and cerebrospinal ﬂuid was performed using statistical
parametrical mapping (SPM; version SPM2, www.ﬁl.ion.ucl.ac.uk/
spm, Institute of Neurology, London, UK). ROIs were deﬁned on
the basis of the segmented MRI and a probabilistic template as
implemented in PVElab [31]. Frontal, parietal, temporal, occipital,
posterior and anterior cingulate, medial temporal and cerebellar
ROIs were used for further analysis. In addition, a global cortical
region was deﬁned consisting of the volume weighted average of
frontal, parietal, temporal and occipital cortices and posterior and
anterior cingulate regions. ROIs were mapped onto dynamic PET
images, generating regional time–activity curves.
The original on-line blood curve was calibrated using whole
blood radioactivity concentrations derived from the seven manual
samples. The calibrated whole blood curve was multiplied with a
single-exponential ﬁt to the plasma-to-whole blood ratios of these
samples, thereby generating a total plasma curve. Finally, the
metabolite corrected plasma input function was obtained by
multiplying this total plasma curve with a sigmoid ﬁt to one minus
the polar metabolite fraction [16, 32]. This method of obtaining the
plasma input function for (R)-[11C]verapamil, corrected for polar
metabolites, has been described in more detail previously [17].
Kinetic analyses were performed using software developed
within Matlab 7.04 (The Mathworks, Natick, MA, USA). (R)-[11C]
verapamil data were analysed using a standard two tissue
compartment model with the regional K1/k2 ratio ﬁxed to the value
obtained for the whole brain grey matter ROI. The volume of
distribution (VT) was used as outcome measure. Again, data
analysis and kinetic modelling procedures have been described in
detail elsewhere [20].
Statistical Analysis
Statistical analyses were performed using SPSS 15.0 (SPSS
Institute, Chicago, IL, USA). Values are presented as mean ±
standard deviation. Potential differences in injected tracer dose,
speciﬁc activity and tracer metabolism (parent and polar metabolite
fraction) were veriﬁed using Students t tests. Comparison of global
and regional differences in VT between age and gender groups was
assessed using both Students t tests and analysis of variance
(ANOVA) with post hoc least signiﬁcance difference (LSD)
testing. Linear regression analyses were performed using VT as
dependent variable and age (continuous) as independent variable.
The threshold for signiﬁcance was set at pG0.05.
Results
Thirty-ﬁve subjects were included in the study, 16 women
and 19 men, divided into three different age groups: young
(age 24±2, range 21–27 years), middle aged (age 46±3,
range 42–50 years) and elderly (age 63±4, range 57–
69 years) (Table 1). Four of the female subjects (two young,
two middle aged) were on oral contraceptives, which were
all stopped in the week of PET scanning. The middle-aged
women included in analyses were aged 43, 43, 44 and 48,
respectively, and were not in the menopause or had reached
postmenopausal status yet. There was no use of hormonal
replacement therapy in female subjects and no use of other
medication in both male and female participants. There were
no differences in injected tracer dose and speciﬁc activity
between the age groups, gender groups or gender groups
within the age groups. One subject (female, middle aged
group, 43 years) was excluded from further analysis because
of technical problems during arterial sampling.
Areas under the curve (AUCs) for both parent and polar
metabolite fractions of (R)-[11C]verapamil were calculated.
Parent fraction AUCs were 38.0±4.1, 35.9±5.1 and 39.5±
4.6 min for young, middle aged and elderly subjects,
respectively. Polar metabolite fraction AUCs were 10.0±
3.2, 8.9±2.5 and 9.3±2.2 min for young, middle aged and
elderly subjects, respectively. In summary, there were no
signiﬁcant differences in tracer metabolism between the age
groups. Similarly, within each age group, there were no
signiﬁcant differences in metabolism between males and
females.
For FBP reconstructed data, signiﬁcant (pG0.05)
increases in (R)-[11C]verapamil VT were found in the elderly
group compared with the young group for frontal, temporal,
posterior and anterior cingulate, medial temporal lobe and
cerebellar regions (Table 2). For PVC OSEM reconstructed
data, similar results were obtained, except that in this case,
also a signiﬁcant increase in VT of the global cortical region
was seen (Table 3). No signiﬁcant differences were seen
between young and middle aged groups and between middle
aged and elderly groups. As effects of PVE correction on
(R)-[11C]verapamil data were minimal (Tables 2 and 3), all
further analyses were performed for FBP reconstructed data.
Within each age group, the effect of gender was assessed.
Results for the global cortical region are shown in Fig. 1,
Table 1. Characteristics of age groups






Young 9 44 24±2 369±14 51±16
Middle 10 50 46±3 368±15 51±22
Old 16 44 63±4 371±35 39±13
n number of subjects, ID injected dose of (R)-[11C]verapamil, SA speciﬁc
activity of the injected (R)-[11C]verapamil
Table 2. Volume of distribution of (R)-[11C]verapamil in several brain
regions for different age groups in case of FBP reconstructed data
Young Middle Old
Global 0.71±0.2 0.75±0.1 0.84±0.2
Frontal 0.71±0.2 0.74±0.1 0.85±0.2*
Parietal 0.70±0.2 0.75±0.1 0.83±0.2
Temporal 0.71±0.2 0.76±0.1 0.86±0.2*
Occipital 0.73±0.2 0.76±0.1 0.85±0.2
Posterior cingulate 0.65±0.1 0.74±0.1 0.82±0.2*
Anterior cingulate 0.66±0.2 0.72±0.1 0.80±0.1*
Medial temporal 0.77±0.2 0.88±0.2 1.07±0.3*
Cerebellum 0.67±0.2 0.74±0.1 0.88±0.2*
*pG0.05 for young versus elderly aged group
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illustrating a signiﬁcantly higher mean VT in young women
than in young men, but no differences in the other age
groups. This also implies that age effects are different for
males and females. Therefore, ANOVA was performed to
assess age effects for each gender separately. For men, a
main effect of age was found for all regions, including the
global cortical region. Post hoc LSD analyses revealed
signiﬁcant differences in VT between young and middle aged
groups for all regions, except frontal and cerebellar ROI. In
addition, signiﬁcant differences between young and elderly
groups were observed for all brain regions. In contrast, in
women, no main effect of age was seen in any of the
regions. Finally, for men and women separately, the
relationship between (R)-[11C]verapamil VT and age was
assessed using linear regression analysis. Regression coef-
ﬁcients and p values are given in Table 4. Again, there was a
main effect of age in men for all regions, but none in
women.
Discussion
This is the ﬁrst study to assess in vivo effects of gender and
aging on human BBB Pgp function in a large sample size
with PET and (R)-[11C]verapamil. This study shows an 18 to
38 % increase in the volume of distribution of (R)-[11C]
verapamil with normal aging in several brain regions, such
as frontal, temporal, medial temporal and anterior and
posterior cingulate regions. These data are consistent with
an age-related decline in BBB Pgp function and are in line
with previous studies assessing BBB Pgp function in vivo
during healthy aging [17–19]. Importantly, the present
results indicate that the effects of age on BBB Pgp function
are driven by men. In women, no main effect of age on Pgp
function was found.
Using PET and [11C]verapamil, three previous studies
have assessed BBB Pgp function in healthy aging. In a pilot
study in ten subjects, ﬁve young and ﬁve elderly males,
Toornvliet and colleagues observed an ~18 % decrease in
Pgp function in the elderly for a whole brain grey matter
region of interest [17]. Bartels and colleagues were the ﬁrst
to study regional differences in Pgp function with aging and
found clusters with higher uptake in white matter regions in
ten elderly compared with seven younger subjects (14
males) using a voxel-based approach [18]. Bauer and
colleagues extended these ﬁndings in thirteen subjects (11
Table 3. Volume of distribution of (R)-[11C]verapamil in several brain
regions for different age groups in case of PVC OSEM reconstructed data
Young Middle Old
Global 0.68±0.2 0.73±0.1 0.82±0.2*
Frontal 0.68±0.2 0.72±0.1 0.84±0.2*
Parietal 0.67±0.2 0.72±0.1 0.81±0.2
Temporal 0.68±0.2 0.75±0.1 0.83±0.2*
Occipital 0.69±0.2 0.73±0.1 0.81±0.1
Posterior cingulate 0.64±0.1 0.73±0.1 0.82±0.2*
Anterior cingulate 0.65±0.2 0.72±0.1 0.79±0.1*
Medial temporal 0.76±0.1 0.91±0.2 1.09±0.4*
Cerebellum 0.65±0.2 0.72±0.1 0.80±0.1*








Fig. 1. Boxplot of volume of distribution (VT) of (R)-[
11C]verapamil for the global cortical brain region for the young, middle
aged and elderly groups. Men are represented by dark grey bars, women by light grey bars. Open circles outliers, VT 0 VT.
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males), in which six older subjects had increased tracer
uptake in several brain regions, although some of these
ﬁndings disappeared after correcting for PVE [19]. These
previous studies used relatively small subject groups and did
not take into account effects of gender on Pgp function.
Furthermore, not all of these studies used the pure
enantiomer (R)-[11C]verapamil, which is the preferred tracer
for quantifying Pgp function [16, 33, 34]. In addition, some
of these studies have used single-tissue compartment models
[17, 19] whilst recent studies have shown that two
components can be identiﬁed in (R)-[11C]verapamil data
[20, 35, 36]. As such, a two-tissue compartment model
provides better ﬁts to (R)-[11C]verapamil data [16, 37].
This difference in age effects on BBB Pgp function seems
to be mainly due to the relatively high distribution volumes
in young female subjects. The reason for this remains
unknown, but it could be due to interindividual differences
in Pgp function itself, or interindividual differences in
(ﬂuctuating) hormone levels in women that, in turn, could
affect Pgp function. It is known that (both endogenous and
synthetic) progesterone/progestins and estrogens can have an
effect on Pgp function [13]. In an attempt to limit these
individual differences in (ﬂuctuating) hormone levels, all
female subjects in both young and middle aged groups were
scanned at comparable time points in their menstrual cycle
(during menstruation). Of course, this does not guarantee
comparable hormone levels or comparable effects of
hormone levels on Pgp function. In the present study, these
hormone levels were not measured. Further studies are
needed to investigate the relationship between (R)-[11C]
verapamil measurements and actual hormone levels. Inter-
estingly, a preclinical study has found differences in brain
uptake of verapamil comparing female mice to male mice,
which suggested a modest increase in Pgp expression and/or
function in female animals [38]. This is in contrast to the
ﬁndings of the present clinical study in humans, in which a
higher VT was found in young women than in young men,
suggesting reduced Pgp function in young women. Further
studies are needed to assess whether this discrepancy is due
to differences in hormonal status or species differences in
transporter expression and/or activity at the BBB. Using
PET and (R)-[11C]verapamil, it is not possible to differen-
tiate between decreased Pgp function due to a decrease in
BBB Pgp expression or due to decreased functionality of the
transporters with intact Pgp expression.
Decreased Pgp function with increasing age could
account for increased drug toxicity and increased CNS side
effects of drugs that are able to pass the BBB in the elderly.
Additionally, older people more often suffer from health
problems, and it is not uncommon that this results in
polypharmacy which often includes the use of Pgp inhibiting
drugs, which may lead to further impairment of the
protective function of Pgp. Furthermore, a decrease in Pgp
function with increasing age could make the elderly more
vulnerable to both exogenous as well as endogenous neuro-
toxins that are transported by Pgp (such as amyloid-beta, the
protein that accumulates in the brain in AD), and this may
contribute to the increasing risk of neurodegenerative
diseases with age. Results of this study suggest decreased
Pgp function in young women compared with young men,
which could implicate that women are exposed to higher
concentrations of neurotoxins earlier in life and therefore
during a longer time period, which in turn could possibly
account for the increased risk of AD in women. Recently,
using PET and (R)-[11C]verapamil, it has been shown that
AD patients have diminished BBB Pgp function compared
with healthy elderly aged subjects, further supporting a
possible role of Pgp in the aetiology of AD [20].
Data in this study were assessed with and without a PVE
correction method, showing comparable results in distribu-
tion volumes. It should be noted that, although the age range
varied from 21 to 69 years, there was no signiﬁcant brain
atrophy present on MRI scans, and as (R)-[11C]verapamil is
a tracer which has low uptake throughout the brain and
therefore shows little contrast, no major effects from PVE
correction methods should be expected.
Strengths of the present study are the relatively large
sample size of the three different age groups and the wide
age range of subjects included, in addition to the quantitative
nature of the study. Nevertheless, a limitation of the study is
that the different age groups still become relatively small
when separated according to gender. In addition, despite
extensive screening, inclusion of subjects with preclinical
neurodegenerative disorders, which by themselves are associ-
ated with decreased Pgp function [20], cannot be excluded.
Conclusions
The volume of distribution of (R)-[11C]verapamil increases
with age in several cortical brain regions, strongly suggest-
ing a progressive decrease in BBB Pgp function with age.
However, this effect is only seen in males, suggesting
different aging patterns between men and women. This
ﬁnding highlights the need to include both males and
females in aging studies.
Table 4. Regional regression coefﬁcients (and corresponding p values) for
linear regression of the volume of distribution of (R)-[11C]verapamil against
age in men and women separately
Men Women
Global 0.64 (0.003) 0.12 (0.672)
Frontal 0.63 (0.004) 0.10 (0.732)
Parietal 0.63 (0.004) 0.10 (0.734)
Temporal 0.65 (0.003) 0.24 (0.465)
Occipital 0.62 (0.005) 0.04 (0.891)
Posterior cingulate 0.58 (0.009) 0.21 (0.443)
Anterior cingulate 0.66 (0.002) 0.14 (0.620)
Medial temporal 0.68 (0.001) 0.42 (0.123)
Cerebellum 0.60 (0.006) 0.30 (0.273)
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